Stock Chart

CRVS

$21.43 +2.14%
Score: 55.5 HOLD
LEAPs: SELL $32
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $32
Premium: $5.57
Expiry: Jan 15, 2027
Target: $33
Score: -76

LEAPs are long-term options (1+ year) with less time decay.
30D Target: $21.5 - $23.52 STRONG_UPTREND
i
30D Trendline Target

This is a PROJECTED price range based on extrapolating the current trendline slope forward 30 days.

How it works:
• Draws support and resistance trendlines
• Calculates slope (rate of change)
• Projects lines to 30 days future

Signals:
● STRONG_UPTREND: Steep rise
● UPTREND: Moderate rise
● SIDEWAYS: Flat/Mixed
● DOWNTREND: Falling

⚠️ Not a prediction. Shows trend projection only.

R-squared: 0.35
Vol: 0.15x (vs SPY: 0.1x | vs QQQ: 0.1x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About CRVS - Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Key Statistics

Market Cap $2B

This CRVS stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track CRVS's price movements with trendlines, gamma walls, and key support/resistance levels.